- 29
- 3 515
Sapient
Приєднався 27 жов 2021
Sapient is a biomarker discovery organization dedicated to accelerating sponsors' drug programs through rapid, large-scale profiling of dynamic biomarkers. Follow our channel to learn more about the immense value metabolite, lipid, and protein biomarkers can bring to drug development, and how Sapient's unique approaches enable rapid identification and validation of circulating biomarkers of health, disease, and drug responsiveness at unprecedented speed and scale.
Cell & Gene Therapy Optimization, a Framework: Assessing Efficacy and Safety with Dynamic Biomarkers
Cell and gene therapies hold enormous potential as new treatment modalities for traditionally difficult-to-treat diseases. There are still challenges, however, stemming from heterogeneity in target engagement and drug response across patients, as well as adverse events. This presentation explores use of discovery mass spectrometry to identify dynamic biomarkers of response and adverse events throughout the course of cell and gene therapy.
Presented by Dr. Mo Jain, Founder and CEO of Sapient
Hosted by AAPS
Presented by Dr. Mo Jain, Founder and CEO of Sapient
Hosted by AAPS
Переглядів: 170
Відео
Case Study: Discovery of Biomarkers of Immuno-oncology
Переглядів 12810 місяців тому
This case study details a program in which Sapient collaborated with Sonia Sharma and Sharma Lab at La Jolla Institute for Immunology to leverage its technologies for nontargeted small molecule biomarker discovery in the setting of immuno-oncology. See data detailing the discovery of biomarkers to identify those individuals who are most likely to respond to these immune-based therapies, as well...
On-Demand Webinar: High-Throughput Biomarker Discovery for Clinical Trial Optimization
Переглядів 183Рік тому
Advances in mass spectrometry resolution and sensitivity have enabled increasingly comprehensive views into the multitude of small molecule metabolites circulating in humans. This webinar, hosted by Oxford Global, discusses how next-generation, high throughput mass spectrometry, advanced data analysis, and population-scale data assets are being leveraged to enable robust discovery of biomarkers...
Timing is Everything: Biomarkers for Early Detection of Preclinical Toxicology Events
Переглядів 219Рік тому
Small molecule biomarkers represent dynamic indicators of adverse effects in the setting of drug exposure and can provide an early warning of drug toxicity prior to histopathological changes. This webinar, hosted by AAPS, explores the use of next-generation mass spectrometry for small molecule biomarker discovery (“metabolomics”) to enable the early detection of toxicology and safety events in ...
Case Study: Discovery of a of Biomarker Biological Processes for a Rare Disease
Переглядів 99Рік тому
In this case study, you'll see how Sapient analyzed samples from over 100 individuals from a rare disease population with sequence-verified mitochondrial disease and found specific small molecules that are altered in these patients. Learn how we validated a key biomarker in independent datasets of patients with mitochondrial disease to confirm its diagnostic value as a readout of mitochondrial ...
Case Study: Discovery of a PD Biomarker to Predict Drug Response
Переглядів 205Рік тому
In this case study, we describe discovery of a pharmacodynamic (PD) biomarker that can be used to rescue a failed Phase III clinical trial by stratifying the patient population into responders vs. non-responders.
Case Study: Discovery of PD-1 Pathway Biomarkers of Target Engagement
Переглядів 209Рік тому
In this case study, we share how Sapient used its Human Biology Database to discover specific biomarkers in circulation that robustly associate with genetic variants present in the PD-1 pathway, and mapped how these pharmacodynamic markers may be influencing underlying treatment response across individuals.
Case Study: Discovery of an early diagnostic biomarker for NASH
Переглядів 188Рік тому
Nonalcoholic steatohepatitis (NASH) is a complex, multifactorial metabolic disorder, influenced by both genetic and environmental factors. While genetic variants linked to NASH heritability have been discovered, our understanding of the pathophysiology that underlies progression from NAFLD to NASH is still incomplete. This case study describes the discovery of a small molecule biomarker that pr...
Experts On... Translating biomarker discoveries into real-world assays | Dr. Phil Worboys
Переглядів 63Рік тому
Dr. Phil Worboys, Head of Translational Science at Sapient, explains how rLC-MS can be leveraged for high throughput, nontargeted discovery screenings, and how biomarkers identified through this method are then validated both biologically and technically to translate the discovery into a robust, targeted assay.
Small molecule biomarkers + adaptive clinical trials: optimize dosing & timing of treatments
Переглядів 56Рік тому
Adaptive clinical trial designs embed flexibility to adjust study protocols during the course of a trial if warranted. Because small molecule biomarkers provide dynamic measures of drug treatment effect, they can be used in adaptive trials to monitor each patient’s biomarker profile over the course of treatment, and adjust therapies based upon profile changes. Watch how.
Experts On... Translating biomarker discoveries made in blood to other matrices | Dr. Phil Worboys
Переглядів 101Рік тому
Sapient's Head of Translational Science, Dr. Phil Worboys, shares how we translate biomarker discoveries made in blood, a matrix that provides a window into organ biology, to other sample matrices such as tissue, urine, or CSF.
Experts On... Partnering in Discovery | Delivering value to sponsors | Dr. Tanya Nguyen
Переглядів 59Рік тому
Dr. Tanya Nguyen, Head of Scientific Operations at Sapient, shares why small molecule biomarkers are needed to complete the picture genetics and proteomics have formed to date, and where sponsors are finding the most value in partnering with Sapient to identify such biomarkers.
Experts On... Partnering in Discovery | Making biomarker discoveries actionable | Dr. Tanya Nguyen
Переглядів 170Рік тому
Sapient's Head of Scientific Operations, Dr. Tanya Nguyen, describes how our integrated, disease-agnostic discovery pipeline can be applied across drug modalities and phases of drug development to identify small molecule biomarkers and provide biological validation for key biomarkers of interest.
The Clinical Trial Conundrum: Identifying Responders vs. Non-Responders
Переглядів 1392 роки тому
Will a patient respond or not respond to the given therapy? That is the fundamental question for any clinical trial - and not an easy answer to predict. Patients are unique; diseases are dynamic and represent heterogenous biology, collectively leading to varied drug response. This presentation explores the use of small molecule biomarkers to improve patient selection and to enrich for responder...
Experts On... Computational Chemistry | Achieving chemical discovery at scale | Dr. Saumya Tiwari
Переглядів 542 роки тому
Dr. Saumya Tiwari, Co-Founder and Head of Computational R&D Operations at Sapient, explains how our platform captures thousands of small molecules across thousands of samples - and what new insights can be gained at this large scale of chemical discovery.
Experts On... Computational Chemistry | The power of ML to boost discovery | Dr. Saumya Tiwari
Переглядів 622 роки тому
Experts On... Computational Chemistry | The power of ML to boost discovery | Dr. Saumya Tiwari
Experts On... Partnering in Discovery | How sponsors are leveraging our pipeline | Dr. Tanya Nguyen
Переглядів 362 роки тому
Experts On... Partnering in Discovery | How sponsors are leveraging our pipeline | Dr. Tanya Nguyen
Genomic + small molecule biomarkers: for a more complete picture of disease risk & progression
Переглядів 192 роки тому
Genomic small molecule biomarkers: for a more complete picture of disease risk & progression
Experts On... Data Science | Amplifying discovery with human biology databases | Dr. Tao Long
Переглядів 542 роки тому
Experts On... Data Science | Amplifying discovery with human biology databases | Dr. Tao Long
Experts On... Data Science | Enabling multi-omics big data analytics | Dr. Tao Long
Переглядів 1262 роки тому
Experts On... Data Science | Enabling multi-omics big data analytics | Dr. Tao Long
Experts On... Data Science | Defining biocomputational approaches | Dr. Tao Long
Переглядів 692 роки тому
Experts On... Data Science | Defining biocomputational approaches | Dr. Tao Long
Fierce Webinar: Population-Scale Biomarker Discovery - Aligning the Right Patient, Disease & Therapy
Переглядів 2102 роки тому
Fierce Webinar: Population-Scale Biomarker Discovery - Aligning the Right Patient, Disease & Therapy
What’s Next in Precision Medicine? Small Molecule Biomarkers to Personalize Diagnostics & Therapies
Переглядів 1072 роки тому
What’s Next in Precision Medicine? Small Molecule Biomarkers to Personalize Diagnostics & Therapies
[Sapient] Discover more, develop faster: biomarker discovery at unprecedented speed & scale
Переглядів 872 роки тому
[Sapient] Discover more, develop faster: biomarker discovery at unprecedented speed & scale
Mapping the Missing Link: Small Molecule Biomarkers to Bridge Gap Between Genetics & Disease Biology
Переглядів 1112 роки тому
Mapping the Missing Link: Small Molecule Biomarkers to Bridge Gap Between Genetics & Disease Biology
Large-Scale Mass Spectrometry Profiling: Accelerated Biomarker Discovery Drives Drug Development
Переглядів 2042 роки тому
Large-Scale Mass Spectrometry Profiling: Accelerated Biomarker Discovery Drives Drug Development
On the Mark: Identifying Non-Invasive Biomarkers of Target Engagement
Переглядів 1672 роки тому
On the Mark: Identifying Non-Invasive Biomarkers of Target Engagement
Smaller, Faster, More Effective: Clinical Trial Enrichment Using Circulating Biomarkers
Переглядів 1432 роки тому
Smaller, Faster, More Effective: Clinical Trial Enrichment Using Circulating Biomarkers
Large Scale Mass Spectrometry Profiling: Accelerated Biomarker Discovery to Drive Drug Development
Переглядів 782 роки тому
Large Scale Mass Spectrometry Profiling: Accelerated Biomarker Discovery to Drive Drug Development
don't normally comment on videos, but I'm glad you been posting more
Very exciting work. End the current Dark Ages of the "give this a shot" approach.